LBA33 Maintenance olaparib plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced high‐grade ovarian carcinoma (HGOC): Final analysis of second progression-free survival (PFS2) in the phase III PAOLA-1/ENGOT-ov25 trial

A. González Martín, Youssef Tazi, Florian Heitz, Laure Montané, Piera Gargiulo, Regina Berger, Kan Yonemori, Ignace Vergote, Alessandra Bologna, Johanna Mäenpää, Cristina Costan, Ulrich Canzler, Claudio Zamagni, E.M. Guerra-Alía, C.-B. Levaché, Frederik Marmé, Elsa Kalbacher, Nikolaus de Gregorio, Nadine Dohollou, Isabelle Laure Ray-Coquard